| Date Filed | Type | Description |
| 10/10/2023 |
SC 13G/A
| WASATCH ADVISORS LP reports a 3.8% stake in Nkarta Inc. |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 • Cash and cash equivalents of $332.1 million on March 31, 2023 • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, today reported financial results for the first quarter ended March 31, 2023. “Nkarta remains focused on the potential of donor-derived CAR NK cell products to broaden access to the transformative power of cell therapy for patients,” said Paul J. Hastings, CEO and President of Nkarta. &#x..." |
|
| 05/10/2023 |
SC 13G/A
| WASATCH ADVISORS LP reports a 10.1% stake in Nkarta Inc. |
| 05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/24/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 04/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/17/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13D/A
| Samsara BioCapital, L.P. reports a 5.9% stake in Nkarta, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/09/2023 |
SC 13G
| WASATCH ADVISORS INC reports a 5.6% stake in Nkarta Inc. |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer SOUTH SAN FRANCISCO, Calif., January 9, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in cell therapy development and continues to lead Nkarta’s global clinical development and regulatory operations. “Dave has been a driving force behind the development and execution of Nkarta’s clinical strategy using off-the-shelf NK cell therapeutics since he joined our organization,” said Paul J. Hastings, President and CEO of Nkarta. “His expertise in the biology and engineering of NK cells, clinical develo..." |
|
| 01/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 12/05/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/16/2022 |
8-K
| Quarterly results |
|